Related Experiment Video

Updated: Oct 13, 2026

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis
09:01

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis

Published on: November 17, 2020

Autoantibodies to myelin basic protein are not present in the serum and CSF of MS patients

K A Brokstad1, M Page, H Nyland

  • 1Department of Microbiology, Gade Institute, University of Bergen, Norway.

Acta Neurologica Scandinavica
|June 1, 1994
PubMed

Insights

This study investigated antibodies against myelin basic protein (MBP) in multiple sclerosis (MS) patients. Researchers found no evidence of MBP antibodies in the sera or cerebrospinal fluid (CSF) of MS patients or controls.

Area of Science:

  • Neuroimmunology
  • Demyelinating diseases

Background:

  • Myelin basic protein (MBP) is a key component of central nervous system (CNS) myelin.
  • Autoimmune responses against MBP are implicated in the demyelination observed in multiple sclerosis (MS).

Purpose of the Study:

  • To investigate the presence of antibodies against MBP in patients with MS.
  • To compare antibody levels in MS patients with those in patients with other neurological diseases and healthy controls.

Main Methods:

  • Sera and cerebrospinal fluid (CSF) samples were collected from 25 MS patients, 25 patients with other neurological diseases, and 16 healthy controls.
  • Antibodies against MBP were detected using radio immunoblot, western blot, radio immunoassay, and enzyme-linked immunosorbent assay (ELISA).

Main Results:

  • No antibodies against MBP were detected in the sera or CSF of multiple sclerosis patients.
  • Similarly, no evidence of MBP antibodies was found in the control groups (other neurological diseases or healthy individuals).

Conclusions:

  • The study found no evidence supporting the role of antibodies against myelin basic protein in the pathogenesis of multiple sclerosis in the studied cohort.
  • Further research may be needed to explore other potential autoimmune targets in MS.

More Related Videos

Scoring Central Nervous System Inflammation, Demyelination, and Axon Injury in Experimental Autoimmune Encephalomyelitis08:17

Scoring Central Nervous System Inflammation, Demyelination, and Axon Injury in Experimental Autoimmune Encephalomyelitis

Published on: February 23, 2024

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...